Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Blood. 2011 Jun 16;117(24):6411-6. doi: 10.1182/blood-2010-12-322214. Epub 2011 Apr 1.
Peripheral blood stem cell transplantation (PBSCT) is the most common transplantation procedure performed in medicine. Its clinical introduction in 1986 replaced BM as a stem-cell source to approximately 100% in the autologous and to approximately 75% in the allogeneic transplantation setting. This historical overview provides a brief insight into the discovery of circulating hematopoietic stem cells in the early 1960s, the development of apheresis technology, the discovery of hematopoietic growth factors and small molecule CXCR4 antagonist for stem- cell mobilization, and in vivo experimental transplantation studies that eventually led to clinical PBSCT. Also mentioned are the controversies surrounding the engraftment potential of circulating stem cells before acceptance as a clinical modality. Clinical trials comparing the outcome of PBSCT with BM transplantation, registry data analyses, and the role of the National Marrow Donor Program (NMDP) in promoting unrelated blood stem-cell donation are addressed.
外周血干细胞移植（PBSCT）是医学领域最常见的移植程序。自 1986 年临床引入以来，它已取代 BM 成为自体移植约 100%和异基因移植约 75%的干细胞来源。本文简要回顾了 20 世纪 60 年代早期发现循环造血干细胞、发展血细胞分离术、发现造血生长因子和小分子 CXCR4 拮抗剂以动员干细胞，以及最终导致临床 PBSCT 的体内实验移植研究。文中还提到了在被接受为临床方法之前，循环干细胞植入潜力的争议。本文还讨论了比较 PBSCT 与 BM 移植结果的临床试验、登记数据分析，以及国家骨髓捐赠计划（NMDP）在促进无关血液干细胞捐赠方面的作用。
